Ardelyx: Buy Rating Maintained Despite Price Target Cut to $11 on IBSRELA Growth and Profitability Potential
at www.tipranks.com (Tue, 10-Nov 6:26 AM)
ARDX Faces a November 16 Lead-Plaintiff Deadline as Securities Class Action Targets XPHOZAH and IBSRELA Access Claims
Market Chameleon (Wed, 21-Oct 11:59 AM)
ARDX faces November 16 lead-plaintiff deadline as lawsuit targets Medicare access and guidance claims
Market Chameleon (Wed, 7-Oct 11:03 AM)
